HLS Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
HLS Therapeutics wird ein Gewinn- und Umsatzwachstum von 49.2% bzw. 8.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 52.4% pro Jahr wachsen soll.
Wichtige Informationen
49.2%
Wachstumsrate der Gewinne
52.4%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 53.6% |
| Wachstumsrate der Einnahmen | 8.6% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 22 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 67 | -7 | N/A | N/A | 1 |
| 12/31/2025 | 61 | -9 | 17 | 17 | 5 |
| 12/31/2024 | 57 | -19 | 4 | 4 | 5 |
| 9/30/2024 | 57 | -22 | 22 | 9 | N/A |
| 6/30/2024 | 59 | -24 | 12 | 12 | N/A |
| 3/31/2024 | 61 | -28 | 12 | 13 | N/A |
| 12/31/2023 | 63 | -28 | 16 | 16 | N/A |
| 9/30/2023 | 63 | -29 | 15 | 16 | N/A |
| 6/30/2023 | 63 | -26 | 4 | 14 | N/A |
| 3/31/2023 | 62 | -26 | 5 | 15 | N/A |
| 12/31/2022 | 61 | -24 | 7 | 17 | N/A |
| 9/30/2022 | 61 | -21 | 7 | 17 | N/A |
| 6/30/2022 | 61 | -19 | 16 | 17 | N/A |
| 3/31/2022 | 60 | -12 | 12 | 15 | N/A |
| 12/31/2021 | 60 | -13 | 12 | 16 | N/A |
| 9/30/2021 | 61 | -16 | 11 | 18 | N/A |
| 6/30/2021 | 59 | -16 | -22 | 17 | N/A |
| 3/31/2021 | 57 | -20 | -28 | 11 | N/A |
| 12/31/2020 | 56 | -15 | -35 | 9 | N/A |
| 9/30/2020 | 54 | -20 | -41 | 6 | N/A |
| 6/30/2020 | 54 | -21 | -9 | 10 | N/A |
| 3/31/2020 | 55 | -16 | 4 | 23 | N/A |
| 12/31/2019 | 54 | -20 | 11 | 26 | N/A |
| 9/30/2019 | 57 | -7 | 11 | 35 | N/A |
| 6/30/2019 | 59 | -25 | 22 | 35 | N/A |
| 3/31/2019 | 61 | -24 | 14 | 28 | N/A |
| 12/31/2018 | 61 | -25 | 18 | 33 | N/A |
| 9/30/2018 | 65 | -26 | 28 | 30 | N/A |
| 6/30/2018 | 70 | -8 | N/A | 33 | N/A |
| 3/31/2018 | 73 | -8 | N/A | 37 | N/A |
| 12/31/2017 | 75 | -6 | N/A | 27 | N/A |
| 9/30/2017 | 71 | -11 | N/A | 25 | N/A |
| 12/31/2016 | 54 | -15 | N/A | 22 | N/A |
| 12/31/2015 | 20 | -10 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: HLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: HLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: HLSDie Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7% pro Jahr).
Hohe Wachstumseinnahmen: HLSDie Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HLS in 3 Jahren voraussichtlich hoch sein wird